Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WinPro: Prometrium in early stage breast cancer
NCT03906669Phase 2Unknown
- Sponsor
- St Vincent's Hospital
- Start
- Mar 2018
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of progesterone in breast cancer (3 arms), sponsored by St Vincent's Hospital. Primary endpoint: Geometric mean suppression of proliferation marker Ki67 at 2 weeks. Status: unknown.
02
Drugs
progesterone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03906669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03906669.